Download PDF
Drug Res (Stuttg) 2018; 68(10): 553-559
DOI: 10.1055/a-0579-7532
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Ethanol Extract of Crataegus Oxyacantha L. Ameliorate Dietary Non-Alcoholic Fatty Liver Disease in Rat

Golbahar Saeedi
1   Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
,
Fereshteh Jeivad
1   Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
,
Mohammadhadi Goharbari
1   Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
,
Gholamreza Hassanzadeh Gheshlaghi
2   Department of Anatomy, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
,
Omid Sabzevari
1   Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
3   Toxicology and Poisoning Research Centre, Tehran University of Medical Sciences, Tehran, Iran
› Author Affiliations
Further Information

Publication History

received 26 November 2017

accepted 12 February 2018

Publication Date:
02 May 2018 (online)

Also available at
    Permissions and Reprints

Abstract

Background Non-alcoholic fatty liver (NAFLD) is one the most prevalent disease worldwide which characterized by fat accumulation in liver with no established efficient therapy. We designed this study to investigate protective and therapeutic effect of Crataegus oxyacantha L. (C. oxyacantha) on NAFLD induced by high fat diet in rat models.

Methods NAFLD was induced by High Fat Diet+fructose (HFD), 45 Wistar rats were divided to 8 groups including control, HFD, HFD+diet change, HFD+diet change+C. oxyacantha 20 mg/kg, co treatment of HFD+C. oxyacantha 10, 20 and 40 mg/kg, and normal diet+C. oxyacantha 40 mg. C. oxyacantha was administered orally. Effectiveness of the C. oxyacantha was assessed through measuring the biochemical factors, and oxidative stress marker (FRAP, GSH, and MDA). Histopathological study was performed using H & E staining.

Results The diet change from high fat to low fat ameliorated liver damage. However, consumption of C. oxyacantha (10 & 20 mg/kg) caused significant reduction in the level of all examined liver biomarkers specially LDH, that showed C. oxyacantha can restore the hepatocyte damage due to HFD. The C. oxyacantha showed a protective effect which was more prominent in the animals treated with the 20 mg/kg C. oxyacantha. The administration of C. oxyacantha caused increased antioxidant status (GSH and FRAP levels) and decreased lipid peroxidation in treated animals.

Major Conclusion Accordingly, C. oxyacantha have both therapeutic and protective effect for NAFLD and may be a potential candidate for further assessments in clinical studies.

Key words

non-alcoholic fatty liver disease - Crataegus oxyacantha L. - liver enzymes - Lipid peroxidation - Antioxidant status - High Fat Diet - fructose
 

  • References

  • 1 Yao H, Qiao YJ, Zhao YL. et al. Herbal medicines and nonalcoholic fatty liver disease. World J Gastroenterol. 2016; 22: 6890-6905
    CrossrefPubMedGoogle Scholar
  • 2 Benlhabib E, Baker JI, Keyler DE. et al. Effects of purified puerarin on voluntary alcohol intake and alcohol withdrawal symptoms in p rats receiving free access to water and alcohol. Journal of Medicinal Food 2004; 7: 180-186
    CrossrefPubMedGoogle Scholar
  • 3 Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: Pathology and pathogenesis. Annu Rev Pathol 2010; 5: 145-171
    CrossrefPubMedGoogle Scholar
  • 4 Lee JS, Jun DW, Kim EK. et al. Histologic and metabolic derangement in high-fat, high-fructose, and combination diet animal models. The Scientific World Journal 2015; 2015: 1-9
    CrossrefPubMedGoogle Scholar
  • 5 Takahashi Y, Sugimoto K, Inui H. et al. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2015; 21: 3777-3785
    CrossrefPubMedGoogle Scholar
  • 6 Del Ben M, Polimeni L, Baratta F. et al. The role of nutraceuticals for the treatment of non-alcoholic fatty liver disease. Br J Clin Pharmacol 2017; 83: 88-95
    CrossrefPubMedGoogle Scholar
  • 7 Oridupa OA, Ovwighose NO, Saba AB. Anti-hyperglycaemic effect of cleome rutidosperma in alloxan-induced diabetic albino rats. Drug research 2017; 67: 719-723
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Seeff LB, Bonkovsky HL, Navarro VJ. et al. Herbal products and the liver: A review of adverse effects and mechanisms. Gastroenterology. 2015; 148: 517-32.e3
    PubMedGoogle Scholar
  • 9 Elahi A, Fereidooni A, Shahabinezhad F. et al. An overview of amenorrhea and respective remedies in Traditional Persian Medicine. Trends in Pharmaceutical Sciences 2016; 2: 3-10
    PubMedGoogle Scholar
  • 10 Raza MA, Mukhtar F, Danish M. Cuscuta reflexa and Carthamus Oxyacantha: Potent sources of alternative and complimentary drug.. SpringerPlus 2015; 4: 1
    CrossrefPubMedGoogle Scholar
  • 11 Wang J, Xiong X, Feng B. Effect of crataegus usage in cardiovascular disease prevention: An evidence-based approach. Evid Based Complement Alternat Med 2013; 2013: 149363
    CrossrefPubMedGoogle Scholar
  • 12 Tassell M, Kingston R, Gilroy D. et al. Hawthorn (Crataegus spp.) in the treatment of cardiovascular disease. Pharmacogn Rev 2010; 4: 32-41 doi: 104103/0973-784765324 2010; 4(7): 32-41
    CrossrefPubMedGoogle Scholar
  • 13 Orhan IE. Phytochemical and pharmacological activity profile of Crataegus oxyacantha L. (hawthorn) – A cardiotonic herb. Curr Med Chem. 2016 Sep 18. [Epub ahead of print]
    PubMed
  • 14 Rahman K, Desai C, Iyer SS. et al. Loss of junctional adhesion molecule a promotes severe steatohepatitis in mice on a diet high in saturated fat, fructose, and cholesterol. Gastroenterology. 2016; 151: 733-746 e12
    PubMedGoogle Scholar
  • 15 Shakibaie M, Shahverdi AR, Faramarzi MA. et al. Acute and subacute toxicity of novel biogenic selenium nanoparticles in mice. Pharmaceutical Biology 2013; 51: 58-63
    CrossrefPubMedGoogle Scholar
  • 16 Ergin M, Caliskanturk M, Senat A. et al. Disulfide stress in carbon monoxide poisoning. Clinical Biochemistry 2016; 49: 1243-1247
    CrossrefPubMedGoogle Scholar
  • 17 Gupta A, Kant S, Gupta SK. et al. Serum FRAP levels and pre-eclampsia among pregnant women in a rural community of Northern India. Journal of Clinical and Diagnostic Research: JCDR 2016; 10: LC12
    PubMedGoogle Scholar
  • 18 Keshavarz-Bahaghighat H, Sepand MR, Ghahremani MH. et al. Acetyl-l-carnitine attenuates arsenic-induced oxidative stress and hippocampal mitochondrial dysfunction. Biological Trace Element Research 2017; 1-14
    PubMedGoogle Scholar
  • 19 Green H, Tobar A, Gafter-Gvili A. et al. Serum Lactate Dehydrogenase is Elevated in Ischemic Acute Tubular Necrosis but Not in Acute Rejection in Kidney Transplant Patients. Prog Transplant 2017; 27: 53-57
    CrossrefPubMedGoogle Scholar
  • 20 Aggarwal BD. Lactate dehydrogenase as a biomarker for silica exposure-induced toxicity in agate workers. Occupational and Environmental Medicine 2014 oemed-2014-102190
    PubMed
  • 21 Jin R, Welsh JA, Le N-A. et al. Dietary fructose reduction improves markers of cardiovascular disease risk in Hispanic-American adolescents with NAFLD. Nutrients 2014; 6: 3187-3201
    CrossrefPubMedGoogle Scholar
  • 22 Davoodi I, Rahimi R, Abdollahi M. et al. Promising effect of Rosa damascena extract on high-fat diet-induced nonalcoholic fatty liver. Journal of Traditional and Complementary Medicine 2017; 7: 508-514
    CrossrefPubMedGoogle Scholar
  • 23 Al Makdessi S, Sweidan H, Mullner S. et al. Myocardial protection by pretreatment with Crataegus oxyacantha: An assessment by means of the release of lactate dehydrogenase by the ischemic and reperfused Langendorff heart. Arzneimittel-Forschung 1996; 46: 25-27
    PubMedGoogle Scholar
  • 24 Akila M, Devaraj H. Synergistic effect of tincture of Crataegus and Mangifera indica L. extract on hyperlipidemic and antioxidant status in atherogenic rats. Vasc Pharmacol 2008; 49: 173-177
    CrossrefPubMedGoogle Scholar
  • 25 Al Humayed S. Protective and therapeutic effects of Crataegus aronia in non-alcoholic fatty liver disease. Archives of Physiology and Biochemistry 2016; 1-8
    PubMedGoogle Scholar
  • 26 Chang CL, Chen HS, Shen YC. et al. Phytochemical composition, antioxidant activity and neuroprotective effect of Crataegus pinnatifida fruit. South African Journal of Botany 2013; 88: 432-437
    CrossrefPubMedGoogle Scholar
  • 27 Edwards JE, Brown PN, Talent N. et al. A review of the chemistry of the genus Crataegus. Phytochemistry 2012; 79: 5-26
    CrossrefPubMedGoogle Scholar
  • 28 Keskin N, Mammadov R, Ili P. The effects of Crataegus aronia var. dentata Browicz extract on biochemical indices and apoptosis in partially hepatectomized liver in rats. Bosnian Journal of Basic Medical Sciences 2012; 12: 177
    CrossrefPubMedGoogle Scholar
  • 29 Ozay C, Mammadov R, Tasdelen G. et al. Potential antioxidant, antiproliferative and hepatoprotective effects of crataegus meyeri. Journal of Food Biochemistry 2015; 39: 548-553
    CrossrefPubMedGoogle Scholar
  • 30 Martinez-Rodriguez JL, Reyes-Estrada CA, Gutierrez-Hernandez R. et al. Antioxidant, hypolipidemic and preventive effect of Hawthorn (Crataegus oxyacantha) on alcoholic liver damage in rats. Journal of Pharmacognosy and Phytotherapy 2016; 8: 193-202
    CrossrefPubMedGoogle Scholar
  • 31 Shanthi S, Parasakthy K, Deepalakshmi PD. et al. Hypolipidemic activity of tincture of Crataegus in rats. Indian J Biochem Biophys. 1994; 31: 143-146
    PubMedGoogle Scholar
  • 32 Akila M, Devaraj H. Synergistic effect of tincture of Crataegus and Mangifera indica L. extract on hyperlipidemic and antioxidant status in atherogenic rats. Vascul Pharmacol 2008; 49: 173-177
    CrossrefPubMedGoogle Scholar
  • 33 Li Z, Xu J, Zheng P. et al. Hawthorn leaf flavonoids alleviate nonalcoholic fatty liver disease by enhancing the adiponectin/AMPK pathway. Int J. Clin Exp Med 2015; 8: 17295-17307
    PubMedGoogle Scholar